Zobrazeno 1 - 10
of 64
pro vyhledávání: '"Kaichiro, Yamamoto"'
Autor:
Kazuhiro Takehara, Aikou Okamoto, Nobuo Yaegashi, Masashi Takano, Hiroyuki Kanao, Toshiharu Kamura, Kaichiro Yamamoto, Toshiaki Saito, Toru Nakanishi, Takahiro Kasamatsu, Kimio Ushijima, Gakuto Ogawa, Tomonori Mizutani, Hiroaki Kobayashi, Harushige Yokota, Toyomi Satoh, Hiroyuki Yoshikawa, Kei Kawana, Takashi Onda, Yoh Watanabe
Publikováno v:
European Journal of Cancer. 130:114-125
Regarding the comparison between primary debulking surgery (PDS) and neoadjuvant chemotherapy (NACT) for stage III/IV ovarian, tubal and peritoneal cancers, EORTC55971 and CHORUS studies demonstrated noninferiority of NACT. Previously, we reported re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9275feb50fb386614d26fd42e4f77afa
https://doi.org/10.1016/j.ejca.2020.02.020
https://doi.org/10.1016/j.ejca.2020.02.020
Autor:
Kaichiro Yamamoto, Niichi Nishiwaki
Publikováno v:
Mathematical Geology and Geoinformatics ISBN: 9780429070891
Mathematical Geology and Geoinformatics
Mathematical Geology and Geoinformatics
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::143ee36fa4149ec61284812bf2ea1e48
https://doi.org/10.1201/9780429070891-15
https://doi.org/10.1201/9780429070891-15
Autor:
Toru Sugiyama, Eiji Hirata, Kouzo Yamada, Satoshi Morita, Koji Hirata, Yasuo Ohashi, Masashi Takano, Yuh Sakata, Takeshi Ikeda, Kaichiro Yamamoto, Yuji Minegishi, Yuichi Ando, Tsutomu Tabata, Masahiro Sugihara, Muneaki Shimada, Takuma Yokoyama
Publikováno v:
Asia-Pacific Journal of Clinical Oncology. 12:115-124
Aim Irinotecan-induced severe toxicities are possibly related to UGT1A1*6 and *28 genotypes. However, the correlation between UGT1A1 polymorphisms and the risk of toxicities induced by low-dose irinotecan plus platinum combination therapy still remai
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d44101098d1a72ae77e33406cfa25d18
https://doi.org/10.1111/ajco.12453
https://doi.org/10.1111/ajco.12453
Autor:
Masao Okadome, Toshiaki Saito, Mikio Mikami, Tsunekazu Kita, Takayoshi Nogawa, Kaichiro Yamamoto, Hideyuki Tanaka, Ken Takizawa, Kayoko Watanabe, Reiko Furuta
Publikováno v:
Journal of Obstetrics and Gynaecology Research. 40:561-569
Aim Few studies have examined the effect of combined low-risk human papillomavirus (LR-HPV) and high-risk human papillomavirus (HR-HPV) infection on the progression of cervical intraepithelial neoplasia (CIN)2 to CIN3. This multi-institutional prospe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bd500658f351a19d31d543be5da9798d
https://doi.org/10.1111/jog.12202
https://doi.org/10.1111/jog.12202
Autor:
Toru Sugiyama, Kaichiro Yamamoto, Tsunekazu Kita, Ken Takizawa, Kazushige Kiguchi, Masamichi Hiura, Ryuichiro Nishimura, Katsumi Mizutani, Nobuo Yaegashi, Satoshi Yamaguchi, Kaneyuki Kubushiro, Katsuji Kokawa
Publikováno v:
Oncology Reports. 28:487-493
The efficacy and adverse events of neoadjuvant chemotherapy with irinotecan hydrochloride and nedaplatin were evaluated in patients with bulky stage Ib2 to IIb cervical squamous cell carcinoma. Eligibility included patients who received irinotecan (6
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5f1cf059191a6012107f20e6d6595c3a
https://doi.org/10.3892/or.2012.1814
https://doi.org/10.3892/or.2012.1814
Autor:
Kimio Ushijima, Kohei Omatsu, Takahiro Kasamatsu, Kazuhiro Takehara, Aikou Okamoto, Hiroaki Kobayashi, Kaichiro Yamamoto, Nobuo Yaegashi, Toyomi Satoh, Toshiaki Saito, Harushige Yokota, Masashi Takano, Takashi Onda, Yoh Watanabe, Masashi Wakabayashi, Hiroyuki Yoshikawa, Kei Kawana, Toru Nakanishi, Toshiharu Kamura, Kenichi Miyamoto
Publikováno v:
Journal of Clinical Oncology. 36:5500-5500
5500Background: We conducted a phase III non-inferiority trial comparing upfront primary debulking surgery (PDS) and neoadjuvant chemotherapy (NAC) for stage III/IV ovarian, tubal and peritoneal ca...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::398c0d49dfd5a408f1fcdcf94439c6ac
https://doi.org/10.1200/jco.2018.36.15_suppl.5500
https://doi.org/10.1200/jco.2018.36.15_suppl.5500
Autor:
Masashi, Takano, Kaichiro, Yamamoto, Tsutomu, Tabata, Yuji, Minegishi, Takuma, Yokoyama, Eiji, Hirata, Takeshi, Ikeda, Muneaki, Shimada, Kouzo, Yamada, Satoshi, Morita, Yuichi, Ando, Koji, Hirata, Masahiro, Sugihara, Toru, Sugiyama, Yasuo, Ohashi, Yuh, Sakata
Publikováno v:
Asia-Pacific journal of clinical oncology. 12(2)
Irinotecan-induced severe toxicities are possibly related to UGT1A1*6 and *28 genotypes. However, the correlation between UGT1A1 polymorphisms and the risk of toxicities induced by low-dose irinotecan plus platinum combination therapy still remains c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::ed0ceefcbe61a7804a4357792d7752f8
https://pubmed.ncbi.nlm.nih.gov/26862009
https://pubmed.ncbi.nlm.nih.gov/26862009
Publikováno v:
Journal of Japan Society of Kansei Engineering. 6:73-78
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0896186e70b38eed8683566d83ea1e71
https://doi.org/10.5057/jjske2001.6.2_73
https://doi.org/10.5057/jjske2001.6.2_73
Autor:
Rikuichi Izumi, Masato Nishida, Tuneo Fujii, Kazuo Hasegawa, Ken Takizawa, Ryuichiro Nishimura, Kaichiro Yamamoto, Hiroshi Fushiki, Tetsuji Tanaka, Naohiko Umesaki
Publikováno v:
Gynecologic Oncology. 95:127-132
Objectives The efficacy and toxicity of combined therapy with irinotecan (CPT-11) plus mitomycin-C (MMC) were evaluated in patients with advanced or recurrent squamous cell carcinoma (SCC) of the uterine cervix. Methods CPT-11 (100 mg/m 2 ) was admin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::774d3f94e605d850534cd865d33d7d19
https://doi.org/10.1016/j.ygyno.2004.06.044
https://doi.org/10.1016/j.ygyno.2004.06.044
Autor:
Masafumi Mushika, Ryuichiro Tsunematsu, Toshio Hirakawa, Toshiaki Saito, Hiroyuki Yoshikawa, Tsuneo Fujii, Toshiharu Kamura, Toshiharu Yasugi, Kaichiro Yamamoto, Noriyuki Katsumata, Takashi Onda
Publikováno v:
Japanese Journal of Clinical Oncology. 34:540-546
The objectives of this phase I trial were to determine the maximum tolerated dose (MTD) and the recommended dose (RD) for phase II/III trials of doxorubicin (DOX) combined with paclitaxel (PTX) and cisplatin (CDDP) in patients with advanced ovarian c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a43bf94cf6cabfee2577766e8bb9c3a5
https://doi.org/10.1093/jjco/hyh098
https://doi.org/10.1093/jjco/hyh098